The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 2 µg/ml. Predicted molecular weight: 147 kDa.
Use a concentration of 10 µg/ml.
FunctionMay act as a GTPase-activating protein for RAB2A, RAB8A, RAB10 and RAB14. Isoform 2 promotes insulin-induced glucose transporter SLC2A4/GLUT4 translocation at the plasma membrane, thus increasing glucose uptake.
Tissue specificityWidely expressed. Isoform 2 is the highest overexpressed in most tissues. Isoform 1 is highly expressed in skeletal muscle and heart, but was not detectable in the liver nor in adipose tissue. Isoform 2 is strongly expressed in adrenal and thyroid gland, and also in lung, kidney, colon, brain and adipose tissue. Isoform 2 is moderately expressed in skeletal muscle. Expressed in pancreatic Langerhans islets, including beta cells (at protein level). Expression is decreased by twofold in pancreatic islets in type 2 diabetes patients compared to control subjects. Up-regulated in T cells from patients with atopic dermatitis.
Post-translational modificationsPhosphorylated by AKT1; insulin-induced. Insulin-stimulated phosphorylation is required for SLC2A4/GLUT4 translocation. Physiological hyperinsulinemia increases phosphorylation in skeletal muscle. Insulin-stimulated phosphorylation is reduced by 39% in type 2 diabetic patients.
Cellular localizationCytoplasm. Isoform 2 shows a cytoplasmic perinuclear localization in a myoblastic cell line in resting and insulin-stimulated cells.
Acrg embryonic lethality (mouse) minimal region ortholog antibody
Acrg embryonic lethality minimal region ortholog antibody
Acrg embryonic lethality mouse minimal region ortholog antibody
Akt substrate of 160 kDa antibody
AS 160 antibody
TBC (Tre 2 BUB2 CDC16) domain containing protein antibody
TBC Tre 2 BUB2 CDC16 domain containing protein antibody
TBC1 D4 antibody
TBC1 domain family member 4 antibody
Anti-TBC1D4 (phospho T642) antibody images
Western blot - TBC1D4 (phospho T642) antibody (ab65753)
All lanes : Anti-TBC1D4 (phospho T642) antibody (ab65753) at 2 µg/ml
Lane 1 : AS160 wild type (WT) Lane 2 : AS160 wild type (WT) with (+) 1 µM insulin treatment for 15 minutes Lane 3 : S588A mutant (S588A) Lane 4 : S588A mutant (S588A) with (+) 1 µM insulin treatment for 15 minutes Lane 5 : T642A mutant (T642A) Lane 6 : T642A mutant (T642A) with (+) 1 µM insulin treatment for 15 minutes
ICC/IF image of ab65753 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal donkey serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab65753, 10µg/ml) overnight at +4°C. The secondary antibody (green) was ab96939, DyLight® 488 donkey anti-sheep IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
References for Anti-TBC1D4 (phospho T642) antibody (ab65753)
This product has been referenced in:
Inazuka F et al. Muscle-specific Knock-out of NUAK Family SNF1-like Kinase 1 (NUAK1) Prevents High Fat Diet-induced Glucose Intolerance. J Biol Chem287:16379-89 (2012).
Read more (PubMed: 22418434) »
Schweitzer GG et al. Sustained postexercise increases in AS160 Thr642 and Ser588 phosphorylation in skeletal muscle without sustained increases in kinase phosphorylation. J Appl Physiol113:1852-61 (2012).
Read more (PubMed: 22936728) »